We believe we are on track to be a leader in prevention, diagnosis, and treatment of cardiovascular diseases. We also realize that alliance with strategic partners can greatly assist in bringing our life-saving diagnostics and therapeutics to those in need as soon as possible.
- info@cardio-theranostics.com
Menu
Menu
NEW STANDARD OF CARE FOR
Cardiovascular Disease
- Discovery
- Diagnostics
- Therapeutics
- Discovery
- Diagnostics
- Therapeutics
CARDIO - THERANOSTICS
New standards of care for Cardiovascular Diseases
We now know why ~130,000 heart attack patients in the USA and millions world-wide experience additional acute damage to the heart, additional loss of heart function, and sometimes even death in the days following a heart attack. We also know why these patients then progress to chronic heart failure in ensuing months leading to a poor quality of life and a 50%, 5-year mortality rate.
Armed with this knowledge, we have identified new pipelines of diagnostics and therapeutics that hold the promise to transform patient care and patient outcomes. Our lead diagnostic identifies heart attack patients at high risk of these adverse outcomes, while our lead acute therapeutic and our lead chronic therapeutic have shown unprecedented potential to suppress the loss of adverse acute and chronic patient outcomes. Both are currently being evaluated in clinical trials.
Our goal is to bring these life-saving diagnostics and therapeutics to patients, reduce overall costs of healthcare for these patients, and meet the needs of pharmaceutical companies for new pipelines of cardiology products.
CARDIO - THERANOSTICS
New standards of care for Cardiovascular Diseases
We now know why ~50% of heart attack patients experience additional damage to the heart (myocardial infarct expansion) in the days following a heart attack and why patients progress to chronic heart failure in ensuing months leading to a dismal quality of life and death of over 300,000 people in the USA.
Armed with this knowledge, we have an unprecedented platform of diagnostics and therapeutics that hold the promise to prevent myocardial infarct expansion and chronic heart failure. Our first therapeutic is currently in a human clinical trial.
Since anyone over the age of 50 can have a heart attack at any time, our goal is to bring these life-saving diagnostics and therapeutics to patients as quickly as possible. To accomplish this goal, we seek pharmaceutical partners and investors to expedite development and commercialization. Our products address block-buster markets to provide exceptional return on investment, while curbing long-term health care costs for this patient population.
wHAT DO WE DO
Our Lead Products
Hemorrhage Diagnostics
Following a heart attack and reperfusion to restore blood flow and oxygen to the heart, nearly 20% of patients bleed within the heart (hemorrhage). Largely through over 20 years of research by the founder of Cardio-Theranostics, we now know that this hemorrhage causes additional, post-reperfusion heart damage (myocardial infarct expansion), re-hospitalization or even death in the days following the heart attack. We also know that hemorrhage also causes long-term chronic heart failure, poor quality of life, and a 50% mortality rate. We encourage you to view the recent podcasts and commentaries below to learn more about the role of hemorrhage in heart attack patient outcomes. Diagnosis of patients at risk of hemorrhage and diagnosing those that experience hemorrhage is therefore essential for guiding early interventions. Yet, current MRI for detection of hemorrhage is contraindicated until several days after a heart attack, leaving physicians blind to potential adverse events. We now have a simple blood diagnostic that enables physicians to determine which heart attack patients entering hospitals are at highest risk of hemorrhage and which of these then experience hemorrhage so that they can receive timely intervention (patent pending).
prevention of additional acute heart damage
Despite considerable efforts, the ability to suppress acute, post-reperfusion heart damage (myocardial infarct expansion) remains unsolved. By understanding the role of hemorrhage in adverse acute patient outcomes, we have discovered an obligate driver of additional post-reperfusion heart damage (myocardial infarct expansion). With this knowledge, we have a lead drug candidate that targets the underlying cause of infarct expansion. The drug candidate has demonstrated unprecedented activity to suppress infarct expansion with maintenance of heart function (left ventricular ejection fraction). A Phase II clinical trial to confirm efficacy in human heart attack patients is currently underway.
Prevention of Chronic Heart Failure
There are no highly effective therapeutics to prevent disease progression to chronic heart failure following a hemorrhagic heart attack. It is a major contributor for why cardiovascular disease remains the number 1 cause of death in the USA and world-wide. Through decades of research, we have identified an obligate driver of disease progression to chronic heart failure. Armed with this knowledge, our lead drug candidate targets the underlying cause of disease progression and holds unprecedented promise to suppress or potentially even cure disease progression to chronic heart failure.
wHAT DO WE DO
Hemorrhage Diagnostics
Following a heart attack and reperfusion to restore blood flow, nearly half of patients have bleeding within the heart (hemorrhage). Hemorrhage is a strong predictor for both near-term loss of even more heart cells (e.g. reperfusion-induced death of cardiomyocytes resulting in myocardial infarct expansion) and long-term chronic heart failure and death. Diagnosis of hemorrhage is therefore essential for preventing near-term and long-term loss of heart function. Yet, current MRI for detection of hemorrhage is contraindicated until several days after a heart attack. Using proteomics, we have identified blood markers that now enable us to determine which heart attack patients have hemorrhage so that they can receive timely intervention (patent pending).
Prevention of Hemorrhage
We now know that bleeding (hemorrhage) in the heart prevents healing and drives a second round of heart muscle cell death (myocardial infarct expansion). We have identified the specific ..Read more
prevention of additional acute heart damage
We now know that bleeding (hemorrhage) in the heart prevents healing and drives a second round of heart muscle cell death (myocardial infarct expansion). We have identified the specific hemorrhage-derived cause and we have multiple therapeutics in preclinical ..Read more
Prevention of Chronic Heart Failure
We now know that bleeding (hemorrhage) in the heart prevents healing and drives a second round of heart muscle cell death (myocardial infarct expansion). We have identified the specific ..Read more
Podcasts
Podcast 1: by Rohan Dharmakumar, Executive Director of the Krannert Cardiovascular Research Center: Founder of Cardio-Theranostics. Medtalk: a brief overview of the role of hemorrhage in heart attack patients.
Podcast 2: by Parallax Apple podast by Rohan Dharmakumar, Executive Director of the Krannert Cardiovascular Research Center: Founder of Cardio-Theranostics. EP 63: Innovation, Research, and the Concept of Hemorrhagic MI https://podcasts.apple.com/us/podcast/parallax-by-ankur-kalra/id1458338104?i=1000551037546 (requires iTunes to listen).
investment opportunities
We believe we are on track to be a leader in prevention, diagnosis, and treatment of cardiovascular diseases. We also realize that alliance with strategic partners can greatly assist in bringing our life-saving diagnostics and therapeutics to those in need as soon as possible.